VHL and nonpapillary renal cell carcinoma: In contrast, many sporadic, advanced VHL−/− ccRCCs treated with Belzutifan after the failure of standard-of-care agents are seemingly HIF2-independent, as are a subset of VHL−/− ccRCC cell lines (15, 16, 31) (https://depmap.org/).